Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it, in partnership with IllinoisGovernor JB Pritzker, has provided $500,000 to the Illinois COVID-19 Response Fund and $500,000 to the Illinois Biotechnology Innovation Organization (iBIO) Institute’s COVID-19 Response Fund.
The Illinois COVID-19 Response Fund will support residents who need access to critical services such as emergency food and basic supplies, interim housing and shelter and primary health care services. The fund will work in tandem with other funds in Illinois to ensure that resources are allocated to those in the most need. The iBIO Institute’s COVID-19 Response Fund will coordinate with the Illinois Manufacturers Association, along with State, corporate, private and philanthropic donations, to make direct purchases of protective medical products to support Illinoisbased healthcare workers and first responders.
“We owe it to the communities where we live and work to provide assistance during times of crisis,” said Timothy Walbert, chairman, president and chief executive officer, Horizon. “We are committed to supporting Illinoisresidents, healthcare workers and first responders during this unprecedented time and hope that other companies in Illinois will join us in providing support to these efforts. In addition to Illinois, we will be providing an additional $500,000 of financial support to other community organizations where we have offices, including Dublin, Ireland, South San Francisco and Washington D.C.”
“As our state responds to the unprecedented challenges posed by COVID-19, businesses, community leaders and organizations across the state are stepping up to help our most vulnerable,” said Governor JB Pritzker. “This fund will partner with existing nonprofits to quickly deploy critical resources to efforts like providing food to seniors and children, support for clinical care facilities, and technology for students who are adapting to remote learning. I’m grateful for the generosity of businesses like Horizon and leaders like Timothy Walbert, coming forward to provide support in this critical time for our state. When this is all over, we will still have each other. Let’s hang onto that comfort — and allow the bonds that connect us to carry us through.”
“Speaking on behalf of the Illinois life science community, we greatly appreciate Governor Pritzker’s leadership during this crisis and Horizon’s leadership as the first company to donate to the iBIO Institute’s COVID-19 Response Fund,” said John Conrad, president and chief executive officer, iBIO. “Thanks to Horizon’s donation, we have already sourced and ordered a large shipment of personal protective equipment. We look forward to announcing other companies, foundations and individual donors that will join us in this urgent and critically important effort. Together we will support the needs of our unsung heroes, the doctors, nurses and first responders who are on the front line battling the COVID-19 pandemic in our state.”
In addition to the broader Illinois support, Horizon is providing financial assistance to ALONE Ireland, the Lake County Crisis Relief Fund, the Chicago Community COVID-19 Response Fund, the Silicon Valley Community Foundation COVID-19 Coronavirus Regional Response Fund and the Greater Washington Community Foundation COVID-19 Emergency Response Fund.
Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.
U.S. Media Contact:
Executive Vice President, Corporate Affairs and Chief Communications Officer
Senior Vice President, Investor Relations
Executive Director, Investor Relations
Ireland Media Contact:
Source: Horizon Therapeutics plc